A trial update was recorded on July 24, 2026 for the study titled "NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer," registered as NCT06379217. Degarelix is associated with this study. The trial is listed as Phase 1. Its current status is active, not recruiting, meaning the study is ongoing but no longer enrolling new participants. The registry entry does not report any results or outcome data as part of this update. No efficacy or safety conclusions are included in the available record. The listing reflects only the administrative status change to active, not recruiting, as of the date given. Readers seeking further detail can consult the official registry entry directly for the full protocol description, eligibility criteria, and any future updates. For general background on degarelix, its approved status, and its typical use, readers can consult the compound overview.
Degarelix Trial NCT06379217 Now Active, Not Recruiting as of Jul 2026
See the full degarelix overview
Source: https://clinicaltrials.gov/study/NCT06379217